12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Benzinga · 04/29 12:07
Gainers
- LogicMark (NASDAQ:LGMK) shares moved upwards by 67.4% to $0.02 during Tuesday's pre-market session.
- Hims & Hers Health (NYSE:HIMS) shares increased by 39.22% to $39.65. The company's market cap stands at $8.8 billion.
- LifeMD (NASDAQ:LFMD) stock rose 19.83% to $7.31. The company's market cap stands at $325.9 million.
- Petros Pharma (NASDAQ:PTPI) stock increased by 15.71% to $0.07. The market value of their outstanding shares is at $1.6 million.
- Aardvark Therapeutics (NASDAQ:AARD) stock increased by 15.61% to $11.7. The company's market cap stands at $250.1 million.
- Tevogen Bio Holdings (NASDAQ:TVGN) shares rose 14.14% to $1.07. The market value of their outstanding shares is at $187.3 million.
Losers
- Iterum Therapeutics (NASDAQ:ITRM) shares decreased by 20.7% to $1.0 during Tuesday's pre-market session. The company's market cap stands at $34.5 million.
- Relmada Therapeutics (NASDAQ:RLMD) stock fell 14.51% to $0.31. The company's market cap stands at $10.1 million.
- Cyclacel Pharmaceuticals (NASDAQ:CYCC) stock fell 14.06% to $0.25. The market value of their outstanding shares is at $3.4 million.
- Universe Pharmaceuticals (NASDAQ:UPC) stock fell 13.45% to $5.15. The company's market cap stands at $78.4 million.
- Ironwood Pharmaceuticals (NASDAQ:IRWD) stock declined by 11.32% to $0.86. The company's market cap stands at $137.7 million.
- Senti Biosciences (NASDAQ:SNTI) shares declined by 9.16% to $3.31. The market value of their outstanding shares is at $85.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.